CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 559 enrolled
Drug / intervention
palbociclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04671615
NCT04671615N/ACompleted
CompareCT.gov

DEMOGRAPHICS, PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS TREATED WITH PALBOCICLIB IN A REAL LIFE SETTING IN ISRAEL

Pfizer·observational·Posted Dec 17, 2020·Updated Dec 10, 2025

In Brief

An observational study evaluating palbociclib for Metastatic Breast Cancer. Completed, enrolled 559 participants across 1 site.

Detailed Summary

The purpose of this study is to understand the treatment patterns, patients and their clinical outcomes in a real life setting in Israel. This study was done in adult breast cancer patients who have started palbociclib combination treatment as per the national basket of health services in January 2018 until August 2020 for all lines of therapy. This study had included adult patients who were prescribed with palbociclib for their breast cancer which had spread to other parts of the body. Patients are followed for around 3.5 years.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesIsrael
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedDec 17, 2020
Enrollment StartDec 6, 2020
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.5 years ago

Interventions

palbociclibdrug

As provided in real world practice